Tumor Immune Response and Immunotherapy in Gastric Cancer.
The remarkable development of immuno-oncology has changed the landscape of gastric cancer (GC) treatment. Because the immunotherapy does not aim the tumor cell directly but intervene to the tumor immune response, understanding of tumor immunity is important. This review paper summarized the tumor immune reaction and immune escape mechanism, focusing the role of T cells and its co-inhibitory signals; immune checkpoint molecules such as PD-1 and PD-L1. And it also described the past clinical trials of immunotherapy for GC patients in details with discussing of its clinical meaning. Strong predictive marker distinguishing the responder is essential to improve the patient's response of the immunotherapy. The microsatellite instability (MSI), Epstein-Barr virus, PD-L1expression, and tumor mutational burden are now regarded as potent predictive markers for immunotherapy of GC patients. Additionally, novel immunotherapy and combination therapy targeting new immune checkpoint molecules such as LAG-3, TIM-3, and IDO has been suggested, and ongoing trials are evaluating its safety and efficacy. Because the immunotherapy is an important treatment option for GC patients and has great potential for improving the patient's outcome, further researches for immuno-oncology should be continuously followed.